{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:31:09Z","timestamp":1781109069326,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Several laboratory tests are used to monitor disease activity and possible complications in patients with inflammatory bowel disease (IBD). Due to limited resources, it is important to identify patients who benefit the most from tight laboratory testing and follow-up. We sought to assess the correlation between a symptom-based clinical activity index and commonly monitored laboratory tests in a large patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The Finnish IBD registry records a validated IBD symptom index questionnaire (IBD-SI) that measures disease activity and the influence of IBD on daily life in patients with ulcerative colitis (UC) and Crohn\u2019s disease (CD). The activity index was compared with the commonly measured laboratory values of fecal calprotectin (FC), hemoglobin (Hb), ferritin, and C-reactive protein (CRP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 5044 IBD patients with 171,967 activity index measurement pairs were included. FC, Hb, and CRP correlated significantly with the activity index in both UC (Spearman\u2019s <jats:italic>r<\/jats:italic> 0.383, \u22120.212, 0.175; <jats:italic>p<\/jats:italic> &lt; 0.001) and CD (Spearman\u2019s <jats:italic>r<\/jats:italic> 0.156, \u22120.176, 0.152; <jats:italic>p<\/jats:italic> &lt; 0.001). No correlation between the activity index and ferritin (Spearman\u2019s <jats:italic>r<\/jats:italic> 0.038 [UC], 0.005 [CD]; <jats:italic>p<\/jats:italic> = 0.020, <jats:italic>p<\/jats:italic> = 0.825) was found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The activity index is a useful tool in the assessment of IBD activity. Active or inactive disease can be identified better, which may be beneficial in planning more personalized follow-up strategies. Tight monitoring of disease can be better targeted to the correct patient population, and the onset of disease flare may be caught at an earlier stage.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00384-025-04829-6","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:33:51Z","timestamp":1739936031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of a clinical activity index in comparison to frequently measured laboratory values in inflammatory bowel disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6748-0184","authenticated-orcid":false,"given":"Marja","family":"Rapo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9494-3573","authenticated-orcid":false,"given":"Pauliina","family":"Molander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-8612","authenticated-orcid":false,"given":"Clas-G\u00f6ran","family":"af Bj\u00f6rkesten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-3711","authenticated-orcid":false,"given":"Suvi","family":"Pakarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-0424","authenticated-orcid":false,"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"4829_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","volume":"20","author":"Y-ZP Zhang","year":"2014","unstructured":"Zhang Y-ZP, Li YY (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20:91\u201399. https:\/\/doi.org\/10.3748\/wjg.v20.i1.91","journal-title":"World J Gastroenterol"},{"key":"4829_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","volume":"139","author":"KT Thia","year":"2010","unstructured":"Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr (2010) Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort. Gastroenterology 139:1147\u20131155. https:\/\/doi.org\/10.1053\/j.gastro.2010.06.070","journal-title":"Gastroenterology"},{"key":"4829_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.crohns.2012.10.007","volume":"7","author":"A Jussila","year":"2013","unstructured":"Jussila A, Virta LJ, Salomaa V, M\u00e4ki J, Jula A, F\u00e4rkkil\u00e4 MA (2013) High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. J Crohns Colitis 7:256\u2013262. https:\/\/doi.org\/10.1016\/j.crohns.2012.10.007","journal-title":"J Crohns Colitis"},{"key":"4829_CR4","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai Z, Wang S, Li J (2021) Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne) 8:765474. https:\/\/doi.org\/10.3389\/fmed.2021.765474","journal-title":"Front Med (Lausanne)"},{"key":"4829_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","volume":"152","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Narula N, Peyrin-Biroulet L (2017) Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 152:351\u2013361. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.046","journal-title":"Gastroenterology"},{"key":"4829_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","volume":"13","author":"AJ Walsh","year":"2016","unstructured":"Walsh AJ, Bryant RV, Travis SP (2016) Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol 13:567\u2013579. https:\/\/doi.org\/10.1038\/nrgastro.2016.128","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4829_CR7","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s10620-017-4770-0","volume":"62","author":"AM Puolanne","year":"2017","unstructured":"Puolanne AM, Kolho KL, Alfthan H, Ristim\u00e4ki A, Mustonen H, F\u00e4rkkil\u00e4 M (2017) Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Dig Dis Sci 62:3123\u20133130. https:\/\/doi.org\/10.1007\/s10620-017-4770-0","journal-title":"Dig Dis Sci"},{"key":"4829_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fmed.2020.00123","volume":"7","author":"P Chen","year":"2020","unstructured":"Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M et al (2020) Serum biomarkers for inflammatory bowel disease. Front Med (Lausanne) 7:123. https:\/\/doi.org\/10.3389\/fmed.2020.00123","journal-title":"Front Med (Lausanne)"},{"key":"4829_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.gastrohep.2016.01.015","volume":"39","author":"P Miranda-Garc\u00eda","year":"2016","unstructured":"Miranda-Garc\u00eda P, Chaparro M, Gisbert JP (2016) Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. Gastroenterol Hepatol 39:508\u2013515. https:\/\/doi.org\/10.1016\/j.gastrohep.2016.01.015","journal-title":"Gastroenterol Hepatol"},{"key":"4829_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000527846","volume":"104","author":"T Sakurai","year":"2023","unstructured":"Sakurai T, Saruta M (2023) Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion 104:30\u201341. https:\/\/doi.org\/10.1159\/000527846","journal-title":"Digestion"},{"key":"4829_CR11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/mib.0000000000001082","volume":"23","author":"A Heida","year":"2017","unstructured":"Heida A, Park KT, van Rheenen PF (2017) Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis 23:894\u2013902. https:\/\/doi.org\/10.1097\/mib.0000000000001082","journal-title":"Inflamm Bowel Dis"},{"key":"4829_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2036.2011.04743.x","volume":"34","author":"D Laharie","year":"2011","unstructured":"Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M et al (2011) Prediction of Crohn\u2019s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 34:462\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04743.x","journal-title":"Aliment Pharmacol Ther"},{"key":"4829_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.crohns.2014.06.012","volume":"9","author":"P Molander","year":"2015","unstructured":"Molander P, F\u00e4rkkil\u00e4 M, Ristim\u00e4ki A, Salminen K, Kemppainen H, Blomster T et al (2015) Does fecal calprotectin predict short-term relapse after stopping TNF\u03b1-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 9:33\u201340. https:\/\/doi.org\/10.1016\/j.crohns.2014.06.012","journal-title":"J Crohns Colitis"},{"key":"4829_CR14","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L et al (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18:2218\u20132224. https:\/\/doi.org\/10.1002\/ibd.22917","journal-title":"Inflamm Bowel Dis"},{"key":"4829_CR15","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3748\/wjg.v20.i13.3542","volume":"20","author":"D Guagnozzi","year":"2014","unstructured":"Guagnozzi D, Lucendo AJ (2014) Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol 20:3542\u20133551. https:\/\/doi.org\/10.3748\/wjg.v20.i13.3542","journal-title":"World J Gastroenterol"},{"key":"4829_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/2050640613518201","volume":"2","author":"D Labaere","year":"2014","unstructured":"Labaere D, Smismans A, Van Olmen A, Christiaens P, D\u2019Haens G, Moons V, Cuyle PJ, Frans J, Bossuyt P (2014) Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2:30\u201337. https:\/\/doi.org\/10.1177\/2050640613518201","journal-title":"United European Gastroenterol J"},{"key":"4829_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc 60:505\u2013512. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4","journal-title":"Gastrointest Endosc"},{"key":"4829_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","volume":"145","author":"SP Travis","year":"2013","unstructured":"Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF et al (2013) Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145:987\u2013995. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.024","journal-title":"Gastroenterology"},{"key":"4829_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/nejm198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625\u20131629. https:\/\/doi.org\/10.1056\/nejm198712243172603","journal-title":"N Engl J Med"},{"key":"4829_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P (2010) Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity. Clin Gastroenterol Hepatol 8:357\u2013363. https:\/\/doi.org\/10.1016\/j.cgh.2010.01.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4829_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/1319-3767.182455","volume":"22","author":"E Koutroumpakis","year":"2016","unstructured":"Koutroumpakis E, Katsanos KH (2016) Implementation of the simple endoscopic activity score in Crohn\u2019s disease. Saudi J Gastroenterol 22:183\u2013191. https:\/\/doi.org\/10.4103\/1319-3767.182455","journal-title":"Saudi J Gastroenterol"},{"key":"4829_CR22","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1097\/mib.0000000000000496","volume":"21","author":"MP Henao","year":"2015","unstructured":"Henao MP, Bewtra M, Osterman MT, Aberra FN, Scott FI, Lichtenstein GR, Kraschnewski J, Lewis JD (2015) Measurement of inflammatory bowel disease symptoms: reliability of an abbreviated approach to data collection. Inflamm Bowel Dis 21:2262\u20132271. https:\/\/doi.org\/10.1097\/mib.0000000000000496","journal-title":"Inflamm Bowel Dis"},{"key":"4829_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM et al (2021) International organization for the study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160:1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"4829_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.mib.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ (2005) Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11:707\u2013712. https:\/\/doi.org\/10.1097\/01.mib.0000173271.18319.53","journal-title":"Inflamm Bowel Dis"},{"key":"4829_CR25","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/s0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Va\u0148\u00e1sek T et al (2017) Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390:2779\u20132789. https:\/\/doi.org\/10.1016\/s0140-6736(17)32641-7","journal-title":"Lancet"},{"key":"4829_CR26","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.3748\/wjg.15.4659","volume":"15","author":"F Gomoll\u00f3n","year":"2009","unstructured":"Gomoll\u00f3n F, Gisbert JP (2009) Anemia and inflammatory bowel diseases. World J Gastroenterol 15:4659\u20134665. https:\/\/doi.org\/10.3748\/wjg.15.4659","journal-title":"World J Gastroenterol"},{"key":"4829_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/gut.2010.228874","volume":"60","author":"AF Goddard","year":"2011","unstructured":"Goddard AF, James MW, McIntyre AS, Scott BB (2011) British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 60:1309\u20131316. https:\/\/doi.org\/10.1136\/gut.2010.228874","journal-title":"Gut"},{"key":"4829_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.mib.0000196646.64615.db","volume":"12","author":"CW Wells","year":"2006","unstructured":"Wells CW, Lewis S, Barton JR, Corbett S (2006) Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 12:123\u2013130. https:\/\/doi.org\/10.1097\/01.mib.0000196646.64615.db","journal-title":"Inflamm Bowel Dis"},{"key":"4829_CR29","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1007\/s10620-022-07474-z","volume":"67","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, Bouguen G, Laharie D, Pellet G, Savoye G, Gilletta C et al (2022) Iron deficiency in patients with inflammatory bowel diseases: a prospective multicenter cross-sectional study. Dig Dis Sci 67:5637\u20135646. https:\/\/doi.org\/10.1007\/s10620-022-07474-z","journal-title":"Dig Dis Sci"},{"key":"4829_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3324\/haematol.2009.017046","volume":"95","author":"G Weiss","year":"2010","unstructured":"Weiss G, Gasche C (2010) Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica 95:175\u2013178. https:\/\/doi.org\/10.3324\/haematol.2009.017046","journal-title":"Haematologica"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-04829-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-04829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:33:54Z","timestamp":1739936034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-04829-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4829"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-04829-6","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board at Helsinki University Hospital (reference number HUS\/23\/2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}